|Bid||17.25 x 900|
|Ask||18.65 x 800|
|Day's Range||17.58 - 18.53|
|52 Week Range||8.86 - 32.48|
|Beta (5Y Monthly)||0.83|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Oct 14, 1999|
|1y Target Est||N/A|
Rite Aid Corp. (RAD) said it saw a 37% decline in sales of items related to colds and the flu during the fourth quarter, thanks to safety precautions taken to combat the COVID-19 pandemic. “This decline was greater than we anticipated and was, of course, driven by everyone continuing to mask up and also certainly from kids not being back socializing at school,” said Heyward Donigan, Rite Aid chief executive, on last week’s earnings call, according to FactSet. Rite Aid wasn’t the only pharmacy retailer to report a sharp decline in cold-and flu-related items during the quarter.
Rite Aid's (RAD) Q4 results gain from RxEvolution strategy, strength in Elixir brand and robust online growth. However, COVID-related costs woes and lesser cases of cough, cold and flu are concerns.
RAD earnings call for the period ending March 31, 2021.